Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a serious lung disease that causes progressive scarring of lung tissue, making it difficult to breathe. The cause is unknown, and it can lead to severe respiratory issues.
We are evaluating the safety and absorption of the inhaled drug CHF10073 in healthy adults, both alone and with itraconazole. This study aims to understand how the drug behaves in the body.
Health conditions and diseases that the clinical trial is designed to study and treat.
Idiopathic Pulmonary Fibrosis (IPF) is a serious lung disease that causes progressive scarring of lung tissue, making it difficult to breathe. The cause is unknown, and it can lead to severe respiratory issues.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.